UnitedHealth Group reported fourth-quarter 2025 revenue of $113.2 billion, missing consensus estimates by approximately $500 million, while adjusted earnings per share of $2.11 matched Wall Street forecasts. Revenue in the UnitedHealthcare segment grew just 3 percent year-over-year, driven by enrollment gains in commercial plans, but Optum services saw only mid-single-digit growth as cost escalation in pharmacy and care delivery moderated top-line expansion. Margins contracted by roughly 40 basis points, reflecting higher medical costs and restructuring charges tied to network optimization initiatives.

On January 27, 2026, UnitedHealth’s share price plunged nearly one-fifth in a single session, erasing tens of billions of dollars in market capitalization and contributing to a broad decline in the Dow Industrial Average. The sell-off was triggered by the company’s weaker-than-expected 2026 revenue guidance and a meager Medicare Advantage rate increase proposal of just 0.09 percent for 2027. Trading volume surged to over ten times its 30-day average, underscoring the scale of investor repositioning amid concerns over reimbursement trends and margin pressure.

Disclosure filings reveal that three U.S. lawmakers executed sizable UnitedHealth stock sales between November and December 2025, days to weeks before the late-January collapse. Representative Kevin Hern sold between $250,001 and $500,000 of UnitedHealth shares on December 23, 2025; Representative Julie Johnson completed two sales in mid-November and mid-December totaling up to $30,000; Representative Gilbert Cisneros sold $1,001–$15,000 on November 12, then bought $15,001–$50,000 on December 19. While no evidence of nonpublic information has emerged, the timing of these transactions has prompted calls for enhanced disclosure rules and heightened scrutiny of legislative stock trading.

UnitedHealth forecast full-year 2026 revenue of approximately $439 billion, falling short of the consensus range of $454–$456 billion. Management cited planned enterprise-wide right-sizing, including expected enrollment declines of up to 2.8 million members in UnitedHealthcare and continued cost pressures in pharmacy and care delivery. Operating income is projected to exceed $24 billion, but investors remain focused on the pace of cost control measures and the impact of Medicare Advantage rate resets on next year’s profit trajectory.